Pneumococcal Disease Prevention and Vaccine Strategies

Streptococcus pneumoniae remains a leading cause of pneumonia, meningitis and sepsis worldwide, particularly among young children and older adults. Prevention hinges on vaccination with polysaccharide and conjugate formulations that target the polysaccharide capsule of defined serotypes. Conjugate vaccines elicit T-cell-dependent immunity, reduce nasopharyngeal carriage and confer herd protection, while polysaccharide vaccines broaden serotype coverage in older age groups but induce a T-cell-independent response. Introduction of higher-valent conjugate vaccines has led to rapid declines in disease caused by vaccine-included serotypes, but has also driven serotype replacement by non-vaccine types of variable invasiveness. Optimising schedules (for example, reduced-dose infant regimens) seeks to balance direct protection and cost-effectiveness. Adult recommendations increasingly consider shared-decision approaches based on individual risk factors, indirect effects from paediatric programmes and circulating serotype patterns. Surveillance of serotype distribution, transmission dynamics and antimicrobial resistance is critical to guide vaccine composition and deployment. Looking ahead, next-generation candidate vaccines that combine conserved protein antigens with polysaccharide conjugates aim to broaden protection against emerging serotypes and reduce antibiotic pressure. Global implementation requires careful alignment of vaccine choice, immunisation schedule and surveillance capacity to sustain declines in both disease burden and resistance.

Research from Nature Portfolio

Recent studies have combined geolocated genomic sequencing with human mobility data to trace the long-term spatial spread of pneumococcal strains and to quantify vaccine-driven shifts in strain fitness and resistance. Modelling of thousands of genomes collected over 15 years in a high-burden country revealed that pneumococci disperse slowly, requiring decades to become widely mixed, and that implementation of conjugate vaccines rapidly decreases fitness of vaccine-included strains. However, non-vaccine serotypes can acquire enhanced fitness and increasing penicillin resistance, indicating that initial declines in resistance may prove transient unless vaccine formulations and deployment strategies continue to evolve.

Pneumococcal Disease Prevention and Vaccine Strategies publication trend

The graph below shows the total number of articles in pneumococcal disease prevention and vaccine strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Serotype: A classification of bacteria based on the chemical structure of their polysaccharide capsule, which determines immune recognition.

Pneumococcal conjugate vaccine (PCV): A vaccine in which capsular polysaccharides from multiple serotypes are chemically linked to a carrier protein to elicit a robust immune response.

Polysaccharide vaccine (PPSV): A vaccine composed of purified capsular polysaccharides that induces B-cell responses without T-cell memory formation.

Herd immunity: Indirect protection conferred to unvaccinated individuals when a sufficient proportion of the population is immune, reducing pathogen circulation.

Vaccine type (VT) / non-vaccine type (NVT): Strains whose capsular serotypes are included (VT) or not included (NVT) in a given vaccine formulation.

Antimicrobial resistance: The ability of bacterial strains to survive or proliferate despite antibiotic treatment, often driven by genetic mutations or acquisition of resistance genes.

References

1. Geographical migration and fitness dynamics of Streptococcus pneumoniae. Nature (2024).
2. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. The Lancet Digital Health (2023).
3. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. The Lancet Infectious Diseases (2024).